Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma
Jithma P. Abeykoon
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorDavid L. Murray
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorIsaiah Murray
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorDragan Jevremovic
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorGregory E. Otteson
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorAngela Dispenzieri
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorBonnie K. Arendt
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorSurendra Dasari
Department of Health Science and Research, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorMorie Gertz
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorWilson I. Gonsalves
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorTaxiarchis V. Kourelis
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorEli Muchtar
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorDavid Dingli
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRahma Warsame
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRonald S. Go
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorMartha Q. Lacy
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorNelson Leung
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorFrancis Buadi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorYi Lin
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRobert A. Kyle
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorVincent Rajkumar
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorShaji Kumar
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorCorresponding Author
Prashant Kapoor
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Correspondence: Prashant Kapoor, Assistant Professor of Medicine and Oncology, Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA.
E-mail: [email protected]
Search for more papers by this authorJithma P. Abeykoon
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorDavid L. Murray
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorIsaiah Murray
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorDragan Jevremovic
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorGregory E. Otteson
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorAngela Dispenzieri
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorBonnie K. Arendt
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorSurendra Dasari
Department of Health Science and Research, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorMorie Gertz
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorWilson I. Gonsalves
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorTaxiarchis V. Kourelis
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorEli Muchtar
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorDavid Dingli
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRahma Warsame
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRonald S. Go
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorMartha Q. Lacy
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorNelson Leung
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorFrancis Buadi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorYi Lin
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRobert A. Kyle
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorVincent Rajkumar
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorShaji Kumar
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorCorresponding Author
Prashant Kapoor
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Correspondence: Prashant Kapoor, Assistant Professor of Medicine and Oncology, Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA.
E-mail: [email protected]
Search for more papers by this authorSummary
Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for MRD, around day-100 post ASCT, 59% were MASS-FIX-positive. At median follow-up of 26 months, 69% of MASS-FIX(+)/NGF(−) patients were alive and progression-free versus 96% of MASS-FIX(-)/NGF(−) patients, P = 0·02. MASS-FIX, a simple peripheral blood-based assay complements marrow-based NGF to accurately prognosticate patients with myeloma.
Conflicts of interest
David L. Murray and Surendra Dasari have intellectual property rights encompassing the MASS-FIX process which have been licensed to The Binding Site. Prashant Kapoor is a PI for research studies for which Mayo Clinic has received funding from AbbVie, Takeda, Sanofi, Janssen and Amgen. Advisory Board: Sanofi, Pharmacyclics, Cellectar and Karyopharm.
Supporting Information
| Filename | Description |
|---|---|
| bjh17195-sup-0001-Suppinfo.docxWord document, 22.4 KB | Data S1. Abeykoon and Kapoor et al. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012; 119: 687–91.
- 2Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015; 125: 1932–5.
- 3Davies FE. Is molecular remission the goal of multiple myeloma therapy? Hematology Am Soc Hematol Educ Program. 2017; 2017: 205–11.
- 4Murray DL, Willrich MAV. Evolution of myeloma testing in clinical chemistry with mass spectrometry. J Appl Lab Med. 2019; 4: 474.
- 5Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017; 92: 772–9.
- 6Zajec M, Langerhorst P, VanDuijn MM, Gloerich J, Russcher H, van Gool AJ, et al. Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-Proteins. Clin Chem. 2020; 66: 421–33.
- 7Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17: e328–e346.
- 8Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017; 31: 2094–103.
- 9Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, et al. Comprehensive assessment of M-Proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016; 62: 1334–44.
- 10Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019; 54: 353–67.
- 11Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L, et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant. 2005; 35: 159–64.
- 12Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant. 2001; 28: 29–37.
- 13Jagannath S. Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymphoma Myeloma. 2007; 7: 518–23.
- 14Kendrick F, Evans ND, Arnulf B, Avet-Loiseau H, Decaux O, Dejoie T, et al. Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma. Front Physiol. 2017; 8: 149.
- 15Mills JR, Barnidge DR, Dispenzieri A, Murray DL. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J. 2017; 7:e590.
- 16Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, et al. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. Br J Haematol. 2020; 189(5): 904–7.
- 17Derman BA, Stefka AT, McIver A, Jiang K, Kubicki T, Jasielec J, et al. Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT. J Clin Oncol. 2020; 38: 8513.
Citing Literature
